一个人工智能衍生的代谢网络预测阿尔茨海默氏症疾病中的精神病
Nha Nguyen1, Jesus J Gomar2, Jack N Truong3
1Center for Neurosciences, The Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA.
Brain communications
|July 2, 2025
概括
一个新的大脑代谢网络,阿尔茨海默氏症精神病网络,准确地区分阿尔茨海默氏症精神病 (AD + P) 和其他形式的阿尔茨海默氏症. 这个网络显示出作为预测和跟踪AD + P进展的生物标志物具有前途.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病精神病 (AD + P) 呈现出妄想和幻觉,导致加速的认知衰退和具有挑战性的患者管理.
- 目前针对AD + P的治疗方法经常重新使用针对精神分裂症开发的药物,突出了针对性治疗的必要性.
- 识别可靠的生物标志物对于区分AD + P和非精神病性阿尔茨海默氏症至关重要,使得更好的治疗开发和患者分层成为可能.
研究的目的:
- 研究一个独特的大脑代谢网络,区分AD + P和非精神病性阿尔茨海默氏症.
- 验证该网络作为预测和监测AD + P的潜在生物标志物.
- 探索网络与认知衰退和特定精神病症状的相关性.
主要方法:
- 使用了来自阿尔茨海默氏病神经成像倡议 (ADNI) 研究的F-18氧葡萄糖正子发射断层扫描 (FDG-PET) 扫描.
- 采用卷积神经网络 (CNN) 来识别和验证阿尔茨海默氏症精神病网络 (APN).
- 分析了网络进展,临床相关性和精神病预测,使用图形理论和表达分数.
主要成果:
- 该APN准确地区分AD + P和控制器,准确率为97%.
- APN分数与增加的认知和功能衰退相关.
- 基于APN的方法预测了阿尔茨海默病中的精神病,准确率为77%,并确定了与精神病有关的特定大脑区域和连接.
结论:
- 阿尔茨海默氏症精神病网络作为AD + P的有希望的生物标志物.
- 这个网络可以帮助患者分层和开发AD + P的新疗法策略.
- 在APN中增加的代谢连接性可能是AD + P特征的妄想和激动行为的基础.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
674
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
相关概念视频
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
